Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Marichal

Vascular & Interventional Radiology Topeka, KS Medical Doctor

NPI 1861602088 CMS profile 1014349

1500 Sw 10Th Ave, Topeka, KS 66604

Open in the dashboard

General payments

$5,401

61 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Marichal of Topeka, KS is reported in the CMS Open Payments database as having received $5,401 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $379 15
2024 General $2,035 10
2023 General $332 6
2022 General $2,250 19
2021 General $183 6
2020 General $46 2
2019 General $177 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Marichal
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Daniel Marichal were reported at $379. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Daniel Marichal Vascular & Interventional Radiology median Middle half National median
2019 $177 $422 $125–$1,555 $163
2020 $46 $200 $68–$652 $114
2021 $183 $280 $99–$866 $132
2022 $2,250 $433 $137–$1,497 $149
2023 $332 $506 $152–$2,019 $160
2024 $2,035 $556 $175–$1,930 $164
2025 $379 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,912 11 payments
  2. Penumbra, Inc. $1,814 9 payments
  3. Inari Medical, Inc. $973 20 payments
  4. Stryker Corporation $350 10 payments
  5. Sirtex Medical Inc $165 2 payments
  6. Bard Peripheral Vascular, Inc. $100 4 payments
  7. Surefire Medical, Inc. $41 2 payments
  8. AngioDynamics, Inc. $20 1 payment
  9. Change Healthcare Technologies, LLC $14 1 payment
  10. Siemens Medical Solutions USA, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,956 8 payments
  2. Food and Beverage $2,445 53 payments
Products named General payments · program years 2019–2025
  1. ELLIPSYS VASCULAR ACCESS SYSTEM $1,912 11 payments
  2. Penumbra System $1,462 4 payments
  3. FLOWTRIEVER CATHETER, S $1,215 26 payments
  4. CT THROMBECTOMY SYSTEM KIT $859 16 payments
  5. Indigo System $352 5 payments
  6. SIR-Spheres Microspheres $165 2 payments
  7. FLOWTRIEVER $161 4 payments
  8. AUTOPLEX $78 1 payment
  9. Venovo $75 3 payments
  10. INTHRILL THROMBECTOMY CATHETER $47 4 payments
  11. Other $92 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Interventional Radiology: 38

Drug cost

$17

Median for Interventional Radiology: $333

Branded share of claims

0%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisone Generic 12 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 250 billing codes

Paid by Medicare

$184,518

Medicare's payments for the services billed

Medicare patients

2,437

Average age 75

Services billed

4,176

1,317 women, 1,120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 37%
Chronic kidney disease 36%
Depression 36%
Ischemic heart disease 35%
COPD 29%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record